Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Depression and Anxiety

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/da.20001PMID 15129420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome.

  2003cited by this paper
• Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline.

  2001cited by this paper
• A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression.

  2000cited by this paper
• Melancholia: A disorder of movement and mood

  1997cited by this paper
• The validity of atypical depression in DSM-IV.

  1996cited by this paper
• Fluoxetine versus phenelzine in atypical depression.

  1996cited by this paper
• The temperament and character inventory (TCI) : a guide to its development and use

  1994influential reference
• A psychobiological model of temperament and character.

  1993influential reference
• Can mildly depressed outpatients with atypical depression benefit from antidepressants

  1992cited by this paper
• Can mildly depressed outpatients with atypical depression benefit from antidepressants?

  1992cited by this paper
• The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

  1992cited by this paper
• Predictive value of symptoms of atypical depression for differential drug treatment outcome.

  1992cited by this paper
• Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design.

  1991cited by this paper
• Response to phenelzine and imipramine in placebo nonresponders with atypical depression

  1991cited by this paper
• Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.

  1989cited by this paper
• Forms of atypical depression and their response to antidepressant drugs.

  1986cited by this paper
• A unified biosocial theory of personality and its role in the development of anxiety states.

  1986cited by this paper
• Nosology of atypical depression

  1983cited by this paper
• SCL-90-R, Administration, Scoring, and Procedures Manual-II for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series

  1983influential reference
• Hysteroid dysphoria.

  1982cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Depressive Classification and Prediction of Response to Phenelzine

  1979cited by this paper
• Assessment of social adjustment by patient self-report.

  1976influential reference
• The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

  1973cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960influential reference
• Effects of Iproniazid in Depressive Syndromes

  1959cited by this paper

• Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials.

  2025cites this paper
• Agentive steadfastness as trait marker in relation to temperament and character.

  2024cites this paper
• Affective disorders and the loudness dependence of the auditory evoked potential: Serotonin and beyond.

  2024cites this paper
• Anxious‐depressive attack and rejection sensitivity—Toward a new approach to treatment‐resistant depression

  2023cites this paper
• An electrophysiological model of major depression: Relevance to clinical subtyping and pharmacological management.

  2021cites this paper
• Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Personalized Approach

  2019cites this paper
• Personality and Brain Disorders: Associations and Interventions

  2019cites this paper
• Evaluating Individual Differences in Patients with Major Depressive Disorder focused on Nine Types Temperament Model

  2019cites this paper
• The development of temperament and character during adolescence: The processes and phases of change

  2018cites this paper
• Use of the Temperament and Character Inventory to Predict Response to Repetitive Transcranial Magnetic Stimulation for Major Depression

  2016cites this paper
• Le trouble aectif saisonnier : la d epression hivernale

  2016cites this paper
• Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.

  2015cites this paper
• Borderline Personality Disorder, Atypical Depression, and Cyclothymia: Diagnostic Distinctions Crossing Mood and Personality Disorders Borders

  2015cites this paper
• Covert Heterogeneity of Major Depressive Disorder: Depression Is More Than the Sum-Score of its Symptoms

  2014cites this paper
• Clinical implications of loudness dependence of auditory evoked potentials in patients with atypical depression.

  2014cites this paper
• Black bile: are elevated monoamines an etiological factor in some cases of major depression?

  2013cites this paper
• Relationship of temperament and character with cortisol reactivity to the combined dexamethasone/CRH test in depressed outpatients.

  2013cites this paper
• Integrating competing dimensional models of personality: linking the SNAP, TCI, and NEO using Item Response Theory.

  2012cites this paper
• A review of Atypical depression in relation to the course of depression and changes in HPA axis organization.

  2012cites this paper
• Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response

  2012cites this paper
• Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?

  2012cites this paper
• A Dimensional Approach to Measuring Antidepressant Response: Implications for Agomelatine

  2012cites this paper
• Etude de l'implication fonctionnelle du système orexinergique dans les mécanismes physiopathogéniques de la dépression majeure

  2011cites this paper
• Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.

  2011cites this paper
• Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms

  2011cites this paper
• The effects of temperament, character, and defense mechanisms on grief severity among the elderly.

  2011cites this paper
• The missing link between clinical endpoints and drug targets in depression.

  2010cites this paper
• Does being moody necessarily imply having a mood disorder rather than a personality disorder

  2009cites this paper
• A psychometric evaluation of the revised Temperament and Character Inventory (TCI-R) and the TCI-140.

  2008cites this paper
• Treatment-Resistant Depression: Critique of Current Approaches

  2008cites this paper
• Classification of Mood Disorders in DSM-V and DSM-VI

  2008cites this paper
• Depressive disorders -- is it time to endorse different pathophysiologies?

  2006influential citation
• Emerging treatments for depression

  2006cites this paper
• Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial

  2006cites this paper
• Treatment of depression with atypical features: a meta-analytic approach.

  2006cites this paper
• Temperament characteristics, as assessed by the tridimensional personality questionnaire, moderate the response to sertraline in depressed opiate-dependent methadone patients.

  2006cites this paper
• Pharmacogenetics in mood disorder

  2005cites this paper
• Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?

  2005cites this paper
• Increased personality disorders and Axis I comorbidity in atypical depression.

  2005cites this paper
• Current awareness in human psychopharmacology

  2004cites this paper
• Evaluation of the effect of bupropion on personality factors in depressed patients

  year unknowncites this paper